Ge Long Hui A P P·2025-11-18 08:43Core Viewpoint - MIRXES-B (02629.HK) has signed a memorandum of understanding with Watson Bio (300142.SZ) to establish a strategic partnership focused on creating an RNA-centered prevention and precision medicine platform, which includes joint development, clinical trials, registration, and sales and distribution [1] Group 1: Partnership Details - The memorandum of understanding is effective for two years from the date of signing [1] - The collaboration aims to leverage the complementary strengths of both companies to advance early detection and preventive medicine, aligning with their long-term goals [1] Group 2: Strategic Implications - This partnership signifies a significant transformation for the company, moving from early detection to prevention and precision medicine [1] - The collaboration is expected to create synergies by combining the company's advanced RNA diagnostic technology and proprietary disease RNA database with Watson's mRNA vaccine technology and strong clinical pipeline [1] Group 3: Operational Capabilities - The partnership will utilize the company's production and regulatory capabilities in the ASEAN region, including the first Industry 4.0 nucleic acid testing and reagent production base in the area [1] - The collaboration will also enhance distribution channels within ASEAN, integrating research and commercial deployment into a cohesive prevention and precision medicine platform [1]